Related Experiment Videos
Lorcainide kinetics and protein binding in patients with end-stage renal disease
Insights
Renal disease does not affect lorcainide pharmacokinetics. This antiarrhythmic drug's dosing and interval likely remain unchanged in patients with end-stage renal disease.
Area of Science:
- Pharmacology
- Nephrology
- Cardiology
Background:
- Lorcainide is an investigational antiarrhythmic medication.
- Ventricular arrhythmias require effective management strategies.
- The impact of end-stage renal disease on drug kinetics is often significant.
Purpose of the Study:
- To investigate the pharmacokinetic profile of lorcainide in patients with end-stage renal disease.
- To determine if renal disease alters lorcainide's elimination half-life or protein binding.
- To provide guidance on lorcainide dosing in patients with impaired renal function.
Main Methods:
- Nine patients with end-stage renal disease received a single 100 mg intravenous bolus of lorcainide.
- Drug kinetics were assessed during both hemodialysis and off-dialysis periods.
- In vitro studies evaluated lorcainide's serum protein binding in various patient populations.
Main Results:
- The elimination half-life (t1/2 beta) of lorcainide was not significantly different between hemodialysis (8.61 ± 6.35 h) and off-dialysis (7.04 ± 4.12 h) periods.
- Serum protein binding of lorcainide remained consistent across normal volunteers, renal patients, and cardiac patients.
- No significant alterations in lorcainide's kinetic properties were observed due to renal disease.
Conclusions:
- End-stage renal disease does not appear to significantly alter the pharmacokinetic profile of lorcainide.
- The findings suggest that current lorcainide dosage and dosing intervals are likely appropriate for patients with renal disease.
- Further clinical studies may be warranted to confirm these pharmacokinetic findings in broader patient cohorts.
Abstract:
Lorcainide is a new antiarrhythmic drug undergoing clinical investigation for management of patients with ventricular arrhythmias. In this study we investigated the kinetic profile of lorcainide in nine patients with end-stage renal disease. A single intravenous bolus of 100 mg of the drug was injected while the patients were undergoing hemodialysis or during the off-dialysis period. Renal disease did not alter the kinetic properties of lorcainide; the elimination t1/2 beta during hemodialysis was 8.61 +/- 6.35 h, not significantly different from 7.04 +/- 4.12 h off-dialysis. Serum protein binding of lorcainide was investigated in vitro, and the percent binding of lorcainide to serum proteins of normal volunteers and renal or cardiac patients was not significantly different. These data suggest that renal disease should not alter either the dose or the dosing interval of lorcainide.